Scientists have found a link between genetics and the likelihood of experiencing side effects from Alzheimer’s drugs. RichVintage/Getty Images Since then, the anti-amyloid medication — donanemab ...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTime TM APOE assay in European countries that accept the CE mark, which will ...
DiamiR Biosciences Corp., a developer of blood-based diagnostics for brain health, and Aptorum Group Limited (NASDAQ:APM), a clinical-stage biopharmaceutical firm, announced that New York State’s ...
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and ...
Revvity, Inc. RVTY announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of ...
Since July 2023, three anti-amyloid medications have been FDA-approved for the treatment of Alzheimer’s disease with more in development. A potential and serious side effect of anti-amyloid ...